Table 1.
Patient characteristics and variables related to anesthesia and surgery
| BIS | NON-BIS | p-value | |
| (n = 120) | (n = 115) | ||
| Gender (male/female) | 70/50 (58; 49-67/42; 33-51) | 75/40 (65; 56-74/35; 26-44) | 0.29 |
| Age (years) | 49 (35, 61) | 47 (34, 61) | 0.85 |
| Height (cm) | 174 (168, 180) | 176 (168, 182) | 0.25 |
| Weight (kg) | 78 (70, 89) | 82 (71, 90) | 0.14 |
| ASA 1 | 42 (34; 26–43) | 49 (43; 33–52) | 0.26 |
| ASA 2 | 65 (55; 45–63) | 50 (43; 34–53) | |
| ASA 3 | 13 (11; 6–18) | 16 (14; 8–22) | |
| Arterial hypertension | 34 (28; 21-37) | 38 (33; 25–42) | 0.48 |
| Heart failure > NYHAII | 0 (0; 0–0) | 3 (2.6; 1–7) | 0.12 |
| Atrial fibrillation | 1 (0.8; 0–5) | 2 (1.7; 0–6) | 0.62 |
| Ischemic heart disease | 4 (3.3; 1–8) | 7 (6.1; 2–12) | 0.37 |
| Peripheral artery disease | 3 (2.5; 1–7) | 0 (0; 0–0) | 0.25 |
| Diabetes | 11 (9.2; 5–16) | 10 (8.7; 4–15) | 1.00 |
| Dyslipidemia | 6 (5; 2–11) | 7 (6.1; 2–12) | 0.78 |
| β-blockersa | 16 (13; 6–18) | 24 (21; 14–29) | 0.16 |
| Antihypertensive drugsb | 33 (28; 20–36) | 39 (34; 25–43) | 0.29 |
| ENT surgery | 103 (86; 78–92) | 94 (82; 73–88) | 0.65 |
| Dermatologic surgery | 13 (11; 6–18) | 15 (13; 7–21) | |
| Ophthalmic surgery | 4 (3; 1–8) | 6 (5; 2–11) | |
| Tracheal tube | 104 (87; 79–92) | 99 (86; 78–92) | 0.90 |
| Laryngeal mask | 16 (13; 8–21) | 16 (14; 8–22) | |
| Fentanyl (μg/kg) | 2.7 (2.3, 2.9) | 2.6 (2.3, 2.9) | 0.61 |
| Mivacuriumd | 97 (81; 73–87) | 93 (81; 72–88) | 0.86 |
| Rocuroniume | 8 (7; 3–13) | 6 (5; 2–11) | |
| Mivacurium (mg/kg) | 0.2 (0.2, 0.3) | 0.2 (0.2, 0.2) | 0.67 |
| Rocuronium (mg/kg) | 0.5 (0.3, 0.5) | 0.5 (0.3, 0.5) | 0.90 |
| Propofol (mg/kg)f | 1.93 (1.7, 2.3) | 2 (2, 2) | 0.74 |
| Propofol airway (mg/kg)g | 2.06 (1.7, 2.4) | 2 (2, 2.5) | 0.07 |
| Propofol eyelash reflex (s)h | 110 (90, 130) | 110 (83, 150) | 0.6 |
| Airway (s)i | 370 (320, 420) | 380 (310, 430) | 0.26 |
| Failed airwayj | 9 (8; 3–14) | 6 (5; 2–11) | 0.60 |
| Vasopressorsk | 13 (11; 6–18) | 14 (12; 7–20) | 0.84 |
| Treatment of hypotensionl | 17 (14; 7–19) | 15 (13; 7–21) | 0.85 |
Continuous variables are presented as median (25%-, 75%-percentile) and discrete variables are presented as number (proportion; 95%-confidence intervals). BIS Bispectral index. ASA Physical status graded according to American Society of Anesthesiologists. NYHA Classification of cardiac failure according New York Heart Association. ENT Ears, nose and throat. aPatients on β-blockers. bPatients on any antihypertensive medication except for β-blockers. cPatients with any cardiovascular disease in their history. dPatients who were administered mivacurium. ePatients who were given rocuronium. fInduction dose of propofol: until BIS < 60 (Group BIS) or fixed weight-related dose (Group NON-BIS). gPropofol dose administered until placement of the airway. hTime from beginning of propofol injection until abolished eyelash reflex. iTime from beginning of propofol injection until placement of the airway excluding patients with failed airway at first attempt. jPatients in whom placement of the airway was not successful at first attempt. kPatients who were administered vasopressors. lPatients who were administered vasopressors, patients in whom head-down tilting was performed and patients who underwent both antihypotensive treatments